Evidence map›Paper›PMID 42013845›Full record

ArticleCell reports. Medicine2026

BDNF insufficiency exacerbates ALS progression.

Yihua Xu, Ji He, Shudan Wang, Yijun Ge, Yichang Jia, Wei Guo, Chen Lv, Xinmeng Yao, Yingying Mao, Fan Mei and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yihua XuSchool of Pharmaceutical Sciences and IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing 100084, China.
Ji HeDepartment of Neurology, Peking University Third Hospital, Beijing 100044, China; Changping Laboratory, Beijing 102206, China.
Shudan WangSchool of Pharmaceutical Sciences and IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing 100084, China.
Yijun GeDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yichang JiaTsinghua-Peking Joint Center for Life Sciences and School of Medicine, Tsinghua University, Beijing 100084, China.
Wei GuoSchool of Pharmaceutical Sciences and IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing 100084, China.
Chen Lv4B Technologies, Limited, Suzhou 215123, China.
Xinmeng YaoSchool of Public Health, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, China.
Yingying MaoSchool of Public Health, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, China.
Fan MeiNeuroscience Research Institute and Department of Neurobiology, School of Basic Medical Sciences, Peking University, Key Laboratory for Neuroscience, Ministry of Education of China and National Health Commission of the People's Republic of China, Beijing 100083, China.
Dongsheng FanDepartment of Neurology, Peking University Third Hospital, Beijing 100044, China; Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing 100191, China. Electronic address: dsfan2010@aliyun.com.
Peng YuanDepartment of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai 200032, China; Institute for Translational Brain Research, Center for Clinical Neuro-AI, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China. Electronic address: pyuan@fudan.edu.cn.
Bai LuSchool of Pharmaceutical Sciences and IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing 100084, China; Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China; Shanghai Academy of Natural Sciences, Shanghai 200031, China. Electronic address: bai_lu@tsinghua.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with progressive loss of motor neurons. Insufficiency of neurotrophic factors is suspected to underlie the disease, but direct evidence remains scarce. In this study, we discover that brain-derived neurotrophic factor (BDNF) val/met mutation, which results in a decrease in BDNF secretion, reduces survival time of ALS patients in two separate cohorts. Using a knockin mouse model of the ALS causal gene FUS

Indexed as

Amyotrophic Lateral SclerosisBrain-Derived Neurotrophic FactorAnimalsDisease Models, AnimalDisease ProgressionHumansMiceMice, TransgenicMotor NeuronsMutationReceptor, trkBRiluzoleRNA-Binding Protein FUSBrain-Derived Neurotrophic FactorReceptor, trkBRiluzoleRNA-Binding Protein FUSALS, BDNF, V66M, FUS, TrkB antibody, B90-1

Identifiers

PMID42013845
PMCPMC13198251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.